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Abstract
Background: Renal function decreases with age. Dosage adjustment according to renal function is indicated for
many drugs, in order to avoid adverse reactions of medications and/or aggravation of renal impairment. There are
several ways to assess renal function in the elderly, but no way is ideal. The aim of the study was to explore renal
function in elderly subjects in nursing homes and the use of pharmaceuticals that may be harmful to patients with
renal impairment.
Methods: 243 elderly subjects living in nursing homes were included. S-creatinine and s-cystatin c were analysed.
Renal function was estimated using Cockcroft-Gault formula, Modification of Diet in Renal Disease (MDRD) and
cystatin C-estimated glomerular filtration rate (GFR). Concomitant medication was registered and four groups of
renal risk drugs were identified: metformin, nonsteroidal anti-inflammatory drugs (NSAID), angiotensin-converting
enzyme -inhibitors/angiotensin receptor blockers and digoxin. Descriptive statistics and the Kappa test for
concordance were used.
Results: Reduced renal function (cystatin C-estimated GFR < 60 ml/min) was seen in 53%. Normal s-creatinine was
seen in 41% of those with renal impairment. Renal risk drugs were rather rarely prescribed, with exception for ACE-
inhibitors. Poor concordance was seen between the GFR estimates as concluded by other studies.
Conclusions: The physician has to be observant on renal function when prescribing medications to the elderly
patient and not only rely on s-creatinine level. GFR has to be estimated before prescribing renal risk drugs, but
using different estimates may give divergence in the results.
Background
Drug elimination through the kidneys is normally
impaired in the elderly, both due to reduced renal blood
flow and perturbations in glomerular filtration rate
(GFR) [1]. In addition, elderly patients have much
comorbidity, such as hypertension, diabetes, and athero-
sclerotic disease, which contribute to reduced renal
f u n c t i o n .T h i si st h em o s ti m portant pharmacokinetic
alteration in the elderly. Most drugs and their active
metabolites are eliminated through the kidneys. There-
fore dosage adjustment according to renal function is
indicated for many drugs, in order to avoid accumula-
tion of the drugs or their metabolites, adverse reactions
and/or aggravation of renal impairment [2]. However, it
has been shown that these adjustments are inadequately
made by clinicians [3,4].
There is no ideal way to assess renal function in the
elderly. Serum creatinine level alone is often very mis-
leading. Many geriatric patients with a “normal” serum
creatinine level actually have a moderate renal impair-
ment when GFR is estimated [4,5]. The use of GFR esti-
mation equations, such as the Modification of Diet in
Renal Disease (MDRD) or the Cockcroft and Gault for-
mula (CG), should increase the awareness among physi-
cians about the accuracy of renal function [6]. However,
there is a variation in creatinine metabolism among
these comorbid patients [7]. The use of cystatin C for
estimating GFR may be a better alternative, since it is
not affected by the muscle volume [8]. There are how-
ever studies showing that cystatin C is not independent
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any medium, provided the original work is properly cited.of body composition [9]. S-cystatin C seems to be a use-
ful marker for estimating GFR in the elderly [10].
There are many common pharmaceuticals that may be
harmful to patients with renal impairment. Metformin is
the first-line drug of choice for patients with type 2 dia-
betes mellitus with beneficial effects on insulin resistance
and hyperglycaemia [11]. However, like all drugs it also
has side effects and the main concern with metformin is
the elevated risk of lactic acidosis. This risk can be mini-
mized by avoiding the drug or adjusting the dose in
patients with renal impairment, advanced coronary or
lung illness, or concomitant use of contrast media.
Nonsteroidal anti-inflammatory drugs (NSAID) are
widely used medications in the treatment of musculos-
keletal disorders, also among elderly [12]. This may be
inadequate, especially when used on regular basis, since
the risk of renal toxicity is obvious in patients with
reduced renal function [2,13,14]. However, even after an
occasional intake of diclofenac, the renal function in
healthy elderly is impaired [15]. Hence, the kidneys are
not only responsible for changes in pharmacokinetics,
but also the target organ of adverse reactions [2].
Angiotensin-converting enzyme inhibitors (ACEI) are
used for the treatment of congestive heart failure, hyper-
tension, for secondary prevention after myocardial
infarction and for slowing the progression of renal dis-
ease [16]. Hyperkalemia does not usually occur in reno-
competent patients, but can be common in patients
with renal impairment, diabetes and those taking medi-
cations which interfere with renal potassium secretion.
Therefore potassium levels should be monitored care-
fully in patients at risk. There is no specific creatinine
level that is an absolute contraindication to ACEI ther-
apy. However, it is recommended to titrate the dosage
slowly when initiating treatment and the target dosage
may have to be reduced [16]. An initial increase of 20
percent in the serum creatinine levels is common, but it
is not an indication for discontinuing the medication.
The same cautions apply when prescribing angiotensin
receptor blockers (ARB) as ACEI.
Digoxin is used as symptomatic treatment in subjects
with heart failure and atrial fibrillation. Morbidity asso-
ciated with the use of digoxin is common due to its nar-
row therapeutic index. The toxicity of digoxin is dose
dependent and is often the result of alterations in renal
function [17]. In patients with renal impairment, digoxin
therapy is associated with an increase in the risk of car-
diac dysrhythmias [18]. For this reason it is recom-
mended to reduce the dose in these patients and the
serum concentration must be monitored carefully.
There is not much research on the population of frail
elderly in nursing homes, although these patients often
have both many medications and reduced renal func-
tion. The aim of this study was to explore the renal
function in elderly subjects in nursing homes by using
different GFR estimates and to investigate the associa-
tion between the estimates. We also (and firstly) wanted
to assess the use of pharmaceuticals that may be harm-
ful to patients with renal impairment. Did the clinicians
take notice of the impaired renal function before
prescription?
Methods
Study population
This study was performed in three municipalities in
southern Sweden: Jönköping, Linköping and Eslöv, as a
part of a larger project, SHADES (Study on Health And
Drugs in Elderly in nursing homes in Sweden). SHADES
is a cohort study, which describes and analyzes mortal-
ity, morbidity and use of pharmaceuticals in people liv-
i n gi nn u r s i n gh o m e si nS w e d e n[ 1 9 ] .T h ea i mo f
SHADES is to use the results to plan interventions giv-
ing better health, less adverse drug reactions and reduce
the number of unplanned hospital admissions. All parti-
cipants in the present study were elderly with multiple
comorbidities, living in nursing homes and aged 65
years or more. All subjects living in the 11 nursing
homes were invited to participate in the study with the
exclusion criteria of severe illness/palliative care or lan-
guage problems. The baseline comprehensive assessment
was performed between March 2008 and September
2009, when 243 of the 315 subjects in the SHADES
study were included
Method
A nurse in each municipality respectively performed the
investigations, which comprised data on concomitant
medication, diagnoses, blood pressure and hospital stays.
Many other variables were investigated for the main
project. Blood samples for analyzes of s-creatinine and
s-cystatin C were taken at the time of inclusion. S-creati-
nine concentrations were measured using the two-point,
fixed-time kinetic Jaffé reaction on an ADVIA 1800 auto-
mated analyzer (Siemens, Deerfield, IL, USA) and cali-
brated to isotope dilution mass spectrometry (IDMS)-
traceable values. S-cystatin C concentrations were mea-
sured using a fully-automated, rapid, particle-enhanced
turbidimetric immunoassay on an ADVIA 1800 auto-
mated analyzer (Siemens, Deerfield, IL, USA). Reference
values for s-creatinine were considered ≤90 μmol/l for
women and ≤100 μmol/l for men. Patient’s weight was
measured. We used the modified MDRD [20] and the
Cockcroft and Gault formulae (CG) for the estimation of
renal function from creatinine. The CG-value was adjusted
for body surface area calculated by the Mosteller’sf o r m u l a
[21]. GFR was also estimated from cystatin C, using the
Grubb formula [22]. In the analyzes we set cut-off points
for GFR at 60 ml/min and 30 ml/min respectively, in
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staging of chronic kidney disease (CKD): GFR > 60 ml/
min stage 1+2 (normal renal function and mild reduction),
GFR 59-30 ml/min stage 3 (moderate reduction) and GFR
< 30 ml/min stage 4+5 (severe reduction and renal failure)
[23].
Within the medication list, four medication groups
were selected for analysis and correlation to renal func-
tion: metformin, NSAIDs, ACE-inhibitors/ARBs and
digoxin. These groups were selected due to an estab-
lished need for dosage adjustment or avoiding according
to renal function and being quite commonly prescribed
in elderly patients. Renal function was in this analysis
estimated from cystatin C, since this estimate is cur-
rently the most commonly used by clinicians in Sweden.
Statistical methods
All statistical analyzes were performed using SPSS statis-
tical package 18.0 (SPSS, Inc. Chicago, IL). We calcu-
lated kappa-value to describe concordance between the
different methods of estimating GFR. Since there is an
ordinal rating of eGFR, we calculated pair wise weighted
k (with squared weights) by the method given by Fleiss
[24]. A kappa value <0.20 is considered poor, fair for
0.21-0.40, moderate for 0.41-0.60, good for 0.61-0.80
and very good for 0.81-1.00.
Ethics
The ethical committee at Linköping University approved
the project no. M 150-07.
Results
In all 243 patients were included. Baseline characteris-
tics of the subjects are presented in table 1. Diagnosis
prevalences are chosen and reported due to the selected
investigated medication groups and their indications.
Cystatin C-estimated GFR was 58.5 ml/min/1.73 m
2
on average. In women with reduced renal function
(cystatin C-estimated GFR < 60 ml/min/1.73 m
2)4 2o u t
of 95 (44.2%) had a normal serum creatinine level (<90
μmol/l). Of men, 11 out of 34 (32.4%) with reduced
renal function had a normal serum creatinine level
(<100 μmol/l). In all 129 subjects had a cystatin C-esti-
mated GFR of less than 60 ml/min/1.73 m
2 and of those
53 (41.1%) had a normal serum creatinine level. In 30
subjects with GFR of less than 30 ml/min 4 patients had
normal serum creatinine levels.
Renal function and staging of all subjects using three
GFR estimates (cystatin C-estimated, Cockcroft - Gault,
modified MDRD) are shown in table 2. Weighted kappa
was 0.42 (95% CI 0.34-0.51) for MDRD-CG, 0.46 (95%
CI 0.36-0.55) for CysC-CG and 0.60 (95% CI 0.52-0.68)
for MDRD-CysC.
Metformin was prescribed to four patients (three
women and one man) and all these had a GFR of more
than 60 ml/min if GFR was estimated from cystatin C
or with the MDRD formula. One patient taking metfor-
min had a GFR of less than 60 ml/min (58.9) according
to the Cockcroft-Gault formula. The median metformin
daily dose was 1.5 g (range 1.5-2.0).
Digoxin prescription for patients in different stages of
renal function is shown in table 3. In all digoxin was pre-
scribed to 19 patients (13 women and 6 men). Of those nine
patients with cystatin C-estimated GFR less than 60 ml/
min/1.73 m
2, four had normal serum creatinine levels. The
median digoxin daily dose was 0.13 mg (range 0.05-0.13).
NSAID prescription for patients in different stages of
renal function is shown in table 4. In all NSAID, i.e.
Table 1 Baseline characteristics of the SHADES study population 2008-2009
Men N = 63 (26%) Women N = 180 (74%)
Mean age/years (range) 82.8 (65-98) 85.7 (65-101)
Mean body mass index (range) 25.1 (16.5-35.9) 25.3 (12.1-41.9)
Number with diabetes mellitus 15 (24%) 34 (19%)
Number with hypertension 18 (29%) 52 (29%)
Number with heart failure 9 (14%) 24 (13%)
Number with atrial fibrillation 11 (17%) 29 (16%)
Number with arthritis/arthrosis 3 (5%) 18 (10%)
Mean number of medications (range) 7.2 (1-14) 7.1 (0-14)
Mean systolic blood pressure/mm Hg (range) 127.0 (85-210) 137.6 (80-215)
Mean diastolic blood pressure/mm Hg (range) 71.5 (30-95) 73.6 (40-110)
Mean serum creatinine level/μmol/L (range) 111.7 (57-609)
a 81.7 (44-223)
Mean cystatin C level/mg/L (range) 1.48 (0.90-4.39) 1.37 (0.71-3.11)
Mean cystatin C- eGFR/ml/min/1.73 m
2 (range) 54.5 (10-101) 59.9 (13-140)
Mean eGFR (Cockcroft-Gault)/ml/min/1.73 m
2 (range) 51.4 (7-101) 50.5 (15-115)
Mean eGFR (MDRD)/ml/min/1.73 m
2 (range) 67.2 (8-118) 64.9 (18-120)
aincluding one patient with exceptionally high level. (The average was 103.7 μmol/L without him.)
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regular use to 4 patients, all women. Of those three
patients with cystatin C-estimated GFR less than 60 ml/
min/1.73 m
2, one had a normal serum creatinine level.
Prescription of ACE inhibitors/ARBs patients in differ-
ent stages of renal function is shown in table 5. The
most common was enalapril with a median daily dose of
10 mg (range 2.5-20). In all these medications were pre-
scribed to 40 patients (28 women and 12 men).
Discussion
This study on frail elderly subjects living in nursing
homes confirms that reduced renal function is common
in this age group. We found that cystatin C-estimated
G F Ro fl e s st h a n6 0m l / m i n / 1 . 7 3m
2 was prevalent in
more than half of the subjects. A study from Iceland
indicates an even higher prevalence, showing that GFR
of less than 60 ml/min occurs in more than 70% of
elderly multimorbid patients [25].
In subjects with renal impairment (<60 ml/min), 46%
had normal levels of s-creatinine. The clinical implica-
tion is that the assessment of renal function must not
be based only on the levels of serum creatinine before
prescribing drugs that may be harmful to elderly sub-
jects with impaired renal function. In a hospital setting,
Corsonello et al found that older patients frequently
have impaired renal function despite normal serum
creatinine levels and this concealed renal insufficiency
leads to an increased risk of adverse drug reactions to
hydrosoluble drugs [26]. Fehrman-Ekholm and Skep-
pholm showed that s-creatinine does not correlate with
age and should therefore not be used as a measurement
of renal function [27]. Furthermore, we found varying
results of GFR when using different estimates. The con-
cordance was moderate to good between MDRD and
cystatin C and moderate concordance between the C-G
and Cystatin C as for C-G and MDRD. The lack of
good concordance between the estimates has also been
shown previously [6,25,28]. Normal renal function,
when considered as a GFR more than 60 ml/min, varied
i nt h i ss t u d yf r o m2 7 %o ft h ep a t i e n t sw h e nu s i n gt h e
Cockcroft-Gault equation, to 61% when applying the
MDRD formula. This is in accordance with previous
findings, where the Cockcroft-Gault equation was
shown to underestimate GFR in the elderly [27,29]. The
National Kidney Disease Evaluation Programme does
not recommend use of the MDRD equation in indivi-
duals with unstable creatinine concentrations, which
includes patients with serious co-morbid conditions and
hospitalized patients, particularly those with acute renal
failure [23]. Consequently any creatinine-based estimat-
ing equation is unreliable when the patient is not in a
steady state. This is important to note, as these patients
often use many drugs and renal function has to be eval-
uated before starting therapy. Cystatin C-estimated GFR
is probably a more accurate measure of renal function
in this frail population [29]. However, cystatin C level
may be elevated in patients with diabetes, thyroid dis-
ease and in those with elevated levels of inflammatory
markers [30] as well as in those treated with steroids
(15 patients in this study with median daily dose of 7.5
mg prednisolone) [31]. In Sweden, electronic reporting
of cystatin C-estimated GFR has been implemented in
s o m er e g i o n s ,b u ti tw a sn o ta v a i l a b l et oa l lc o m m u -
nities that were included. A new, possibly valuable esti-
mation equation of GFR is CKD-EPI developed by
Levey et al [32], but this is not used in clinical practise
in Sweden. It is obvious that the divergences between
the estimates may cause different prescribing patterns
and also more or less caution with renal risk drugs or
Table 2 Renal function by three different estimates
eGFR/CRcl (ml/min/1.73 m
2)
>60 59-30 <30
Cystatin C-estimated
a 114 (46.9%) 99 (40.8%) 30 (12.3%)
Cockcroft-Gault
a 66 (27.2%) 148 (60.9%) 29 (11.9%)
MDRD
a 149 (61.3%) 82 (33.8%) 12 (4.9%)
Presented as number of patients (%)
an = 243.
Table 3 Number of patients in different GFR stages that
were prescribed digoxin
eGFR/CRcl (ml/min/1.73 m
2)
>60 59-30 <30
Cystatin C-estimated
a 10 8 1
Cockcroft-Gault
a 61 30
MDRD
a 13 6 0
an = 19.
Table 4 Number of patients in different GFR stages that
were prescribed NSAID
eGFR/CLcl (ml/min/1.73 m
2)
>60 59-30 <30
Cystatin C-estimated
a 121
Cockcroft-Gault
a 121
MDRD
a 220
an=4 .
Table 5 Number of patients in different GFR stages that
were prescribed ACEI/ARB
eGFR/CRcl (ml/min/1.73 m
2)
>60 59-30 <30
Cystatin C-estimated
a 14 20 6
Cockcroft-Gault
a 11 23 6
MDRD
a 22 14 4
an = 40.
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of GFR the physician uses.
In this study population, the investigated renal risk
drugs were rather rarely prescribed, especially metfor-
min (4 patients) and NSAID (4 patients). This may indi-
cate awareness among the prescribers of renal
impairment in the elderly population and the accompa-
nied risk when prescribing medications. The awareness
of this risk of metformin appears higher than previously
reported. In an out-patient clinic in Palestine 60% of the
patients treated with metformin had at least one contra-
indication [33] and a Thai study showed that over 80%
of patients with type 2 diabetes with contraindication
for metformin were using this medication [34].
The exception in our study is ACE-inhibitors/ARB,
which were prescribed to 40 patients. These medications
however, are also renoprotective and should thus be
considered for this group of patients. Many of the sub-
jects using ACE-inhibitors/ARB had reduced GFR (65%
when cystatin C-estimated). This may represent an
intentional use for these patients as renoprotection.
However, one has to be observant and the potassium
levels should be strictly monitored. The use of diuretics
was frequent, 100 patients, and this may of course also
affect potassium levels.
Almost half of the subjects taking digoxin had reduced
GFR (<60 ml/min). This may be risky, due to the nar-
row therapeutic index of digoxin. There is an obvious
risk that GFR is gradually decreasing even more, with
the subsequent accumulation and adverse reactions.
Sweileh et al found that digoxin was one of the most
commonly prescribed inappropriate medications in
patients with renal insufficiency [35]. Accordingly,
digoxin is one of the medications frequently seen in
patients admitted to hospital due to adverse reactions
[36]. Probably the prescribers of the patients in our
study had only observed s-creatinine before initiating
the digoxin therapy, since almost half of the subjects
with renal impairment had normal levels of s-creatinine.
It is however not surprising that 19 patients were pre-
scribed digoxin, since as many as 40 patients had
chronic atrial fibrillation.
This study has some limitations. First, we only used
different estimates for calculating GFR and did not have
any true values of GFR to compare with, i.e. iohexol
clearance. Second, this study investigated only the frail-
est and most multimorbid patients and the results can-
not therefore be generalized to the entire population of
elderly. On the other hand, the clinical relevance of the
study is high, since these frail patients are more sensitive
to adverse reactions and hence, the physician has to be
extraordinary observant on renal function. It is possible
that the reported diagnoses are not complete, since they
are collected from the medical records and since some
of the patients may be treated in relation to symptoms
without a diagnosis. The included nursing homes, and
hence the investigated patients, were not randomly
selected but were conveniently sampled. The present
study was a cross-sectional study and therefore it was
not possible to state if s-creatinine was a stable value.
There was however no clinical suspicion of any patient
having an acute kidney injury. Since it is a cross-
sectional study, we cannot know whether the NSAID
use was permanent or for limited-time use. There were
no details available about possible attempts to adjust the
drugs for renal dosing. It is possible that drug use lead-
ing to adverse reactions was not captured, but only
medications in patients who tolerate being on these
renal risk medications.
Since impaired renal function is common among the
elderly, further research is needed in this area. More
knowledge about how to estimate renal function in a
simple and precise way would be valuable. More
research is also required about medications used for this
population, so that guidelines for dosage, therapy initiat-
ing and possible interactions will be evidence based.
Conclusions
We report that reduced renal function is common
among frail elderly subjects living in nursing homes,
although nearly half of those with renal impairment
have a normal creatinine level. Lack of good concor-
dance was found between the different GFR estimates
used. In this study population, the investigated renal
risk drugs were rather rarely prescribed, implicating
awareness among physicians about the risks. The clinical
implication of this study is that the physicians have to
be cautious when prescribing medications that may be
harmful to elderly subjects with renal impairment and
this decision should not be based solely on serum creati-
nine levels. GFR has to be estimated before prescribing
renal risk drugs, but using different estimates may give
different results.
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